➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Express Scripts
AstraZeneca
McKinsey
McKesson

Last Updated: June 7, 2020

DrugPatentWatch Database Preview

QNASL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Qnasl, and what generic alternatives are available?

Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-two patent family members in thirty-two countries.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

US ANDA Litigation and Generic Entry Outlook for Qnasl

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

US Patents and Regulatory Information for QNASL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014 RX Yes No   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for QNASL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014   Start Trial   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012   Start Trial   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Express Scripts
AstraZeneca
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.